Neoplasms

All Conditions

Blood and Lymph Conditions

Nutritional and Metabolic Diseases

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Anemia

Anemia, Iron-Deficiency

Iron Deficiencies

Nasopharyngeal Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Hematologic Diseases

Metabolic Diseases

Iron Metabolism Disorders

Anemia, Hypochromic

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Micronutrients

All Drugs and Chemicals

Hematinics

Mineral

Iron

Iron isomaltoside 1000

Ferric Compounds

Trace Elements

Iron Supplement

Patients receive iron Isomaltide after anti-tumor therapy.

Patients receive polysaccharide iron complex after anti-tumor therapy.

Patients receive Iron isomaltoside after IC and CCRT

Iron Isomaltoside 1000

Patients receive Polysaccharide Iron Complex Pill after IC and CCRT

Polysaccharide Iron Complex Pill

All patients received intensity-modulated radiotherapy before enrolled.

Intensity-modulated radiotherapy

Qiu Yan Chen, Dr

Shan Shan Guo, Dr

Haiqiang Mai, MD,Ph.D

Qiuyan Chen, MD,Ph.D

Shanshan Guo, MD,Ph.D

Primary purpose： To evaluate the difference of hematopoietic response rate at 1 month after concurrent chemoradiotherapy between iron isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma.

Secondary purpose:

To evaluate the difference of hematopoietic response rate, tolerance, acute side effects, qualtiy of life at 2 months and 3 months after concurrent chemoradiotherapy between Iron Isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma.

Iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma will be enrolled and receive iron Isomaltide or oral iron supplement after randomised. The hematopoietic response rate, tolerance, acute side effects, qualtiy of life and long time survival would be evaluated.

Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

A Randomised Phase II Trial of Iron Isomaltide Versus Oral Iron Supplement for Radiotherapy or Chemotherapy Associated Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

Hematopoietic response rate at one month after IC+CCRT.

Hematopoietic response rate at two months after IC+CCRT.

Hematopoietic response rate at three months after IC+CCRT.

The acute side effects of iron isomaltide

The scores of each scale of quality of life questionaires for FACT-An

The difference of HGB after patients receiving iron supplements

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma	NCT05913414	Nasopharyngeal ... Iron-deficiency Anemia	Iron Isomaltosi... Polysaccharide ... Intensity-modul...	18 Years - 65 Years	Sun Yat-sen University
Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma	NCT05913414	Nasopharyngeal ... Iron-deficiency Anemia	Iron Isomaltosi... Polysaccharide ... Intensity-modul...	18 Years - 65 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for polysaccharide iron complex pill